Orphan drug kicks off EMA project to involve patients in benefit-risk assessments
This article was originally published in SRA
In a move intended to give patients more of a say in the evaluation of new drugs, the European Medicines Agency has begun a project under which patients will be invited to take part in certain benefit-risk discussions at meetings of its main scientific committee, the CHMP1,2. The project has kicked off with Clinuvel's Scenesse (afamelanotide), a new drug intended to treat the rare disease erythropoietic protoporphyria (EPP).
You may also be interested in...
Valneva is scaling up manufacture of its coronavirus vaccine alongside the clinical development program, with a view to meeting its commitment to provide millions of doses for use in the UK and the EU.
The UK government says it will begin a consultation on a future falsified medicines scheme for Great Britain within a year after the passage of new legislation on medicines and medical devices. Moves are also under way to ensure the smooth supply of medicines from GB to Cyprus, Ireland, Malta and Northern Ireland.
The team behind Russia’s first COVID-19 vaccine has asked for scientific advice from EU drug regulators in view of a possible submission for marketing authorization.